Market Research Future published a Half-Cooked research report on “Global TMJ Disorders
Market Research Report - Forecast to 2023” – Market Analysis, Scope, Stake, Progress,
Trends and Forecast to 2023.
TMJ (temporomandibular joint and muscle) disorder is a medical condition which causes
dysfunction and pain in the jaw joint and the muscles that control jaw movement. The
medical condition is diagnosed more frequently in women than the men. According to the
American Academy of Orofacial Pain, TMJ disorders may have more than one symptoms and
causes. Some of the major symptoms of this disorder are aching facial pain, tenderness or
pain in jaws, pain while chewing etc. TMJ disorders can occur if the joint's cartilage is
damaged by arthritis or by a blow or other impact or the disk erodes or moves out of its
proper alignment.
According to the recent study report published by the Market Research Future, global TMJ
disorders market is booming and expected to gain prominence over the forecast period. The
market is projected to demonstrate a sound growth by 2023, surpassing its previous growth
records in terms of value with a striking CAGR during the anticipated period (2017 – 2023).
The major drivers will be the increasing prevalence of TMJ disorder, rising healthcare
expenditures and growing awareness for the oral health. According to the National Institute
of Dental and Craniofacial Research in 2014, the prevalence of temporomandibular joint and
muscle disorder (TMJD) was in between 5% to 12%. Moreover, according to the Centers for
Medicare & Medicaid Services in 2016, the U.S. healthcare expenditure was about USD 3.3
trillion, which accounted for 17.9% of the total GDP within the same year.
However, lack of awareness and low per capita healthcare expenditure in the middle and
low income countries may restrain the market growth during the forecast period.
Get Premium Sample Copy @
https://www.marketresearchfuture.com/sample_request/4090 .
Global TMJ Disorders Market - Competitive Analysis
Characterized by the presence of several well-established and small players, the TMJ
disorders market appears to be highly competitive and fragmented. International players
are increasingly expanding their footprint in the developing economy, making it difficult for
regional vendors to compete with them, especially in terms of features such as product
differentiation, product portfolios, quality, and pricing. The market is witnessing intensified
competition which is expected to get more intensified further during the forecast period. The
intense competition prevalent in the market dictates the consolidation among marketers.
Well established players incorporate acquisition, collaboration, partnership, expansion, and
product launch in order to gain competitive advantage in this market and to maintain their
market position.
Pfizer Inc. is a U.S. based biopharmaceutical company and plays a significant role in the TMJ
disorders market. The company’s total revenue was about USD 52,824 million in 2016.
Moreover, it was estimate that the company spent 14.9% of its total revenue in research
and development which made the company to improve its position in the global market and
enhance its product portfolio.
In August 2016, FDA approved Pfizer's TROXYCA ER extended-release capsules CII for pain
management.
In March 2017, ALLERGAN announced that the company has received approval from the
U.S. Food and Drug Administration (FDA) to market JUVÉDERM VOLLURE XC, for correction
of moderate to severe facial wrinkles and folds, such as nasolabial folds, in adults over the
age of 21.